KR20250021303A - Lmna 돌연변이 보인자에 대한 치료에 사용하기 위한 안티센스 핵산 - Google Patents

Lmna 돌연변이 보인자에 대한 치료에 사용하기 위한 안티센스 핵산 Download PDF

Info

Publication number
KR20250021303A
KR20250021303A KR1020247036183A KR20247036183A KR20250021303A KR 20250021303 A KR20250021303 A KR 20250021303A KR 1020247036183 A KR1020247036183 A KR 1020247036183A KR 20247036183 A KR20247036183 A KR 20247036183A KR 20250021303 A KR20250021303 A KR 20250021303A
Authority
KR
South Korea
Prior art keywords
nucleic acid
allele
lmna
expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036183A
Other languages
English (en)
Korean (ko)
Inventor
이갈-마르틴 핀토
안케 요한나 마리나 티센
딜런 크리스탄토 드 브리스
Original Assignee
스티칭 암스테르담 유엠씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티칭 암스테르담 유엠씨 filed Critical 스티칭 암스테르담 유엠씨
Publication of KR20250021303A publication Critical patent/KR20250021303A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020247036183A 2022-03-30 2023-03-30 Lmna 돌연변이 보인자에 대한 치료에 사용하기 위한 안티센스 핵산 Pending KR20250021303A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22165710 2022-03-30
EP22165710.9 2022-03-30
PCT/NL2023/050168 WO2023191631A1 (en) 2022-03-30 2023-03-30 Antisense nucleic acids for use in the treatment for lmna mutation carriers

Publications (1)

Publication Number Publication Date
KR20250021303A true KR20250021303A (ko) 2025-02-12

Family

ID=81074125

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036183A Pending KR20250021303A (ko) 2022-03-30 2023-03-30 Lmna 돌연변이 보인자에 대한 치료에 사용하기 위한 안티센스 핵산

Country Status (9)

Country Link
US (1) US20260002152A1 (https=)
EP (1) EP4499826A1 (https=)
JP (1) JP2025513932A (https=)
KR (1) KR20250021303A (https=)
CN (1) CN119790153A (https=)
AU (1) AU2023246365A1 (https=)
CA (1) CA3246987A1 (https=)
MX (1) MX2024012034A (https=)
WO (1) WO2023191631A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096498A1 (en) * 2023-10-30 2025-05-08 Research Institute At Nationwide Children's Hospital Compositions and methods for treating diseases or conditions associated with progerin expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
WO2007047913A2 (en) * 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
WO2020061497A1 (en) * 2018-09-20 2020-03-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of lmna expression

Also Published As

Publication number Publication date
WO2023191631A1 (en) 2023-10-05
JP2025513932A (ja) 2025-04-30
US20260002152A1 (en) 2026-01-01
AU2023246365A1 (en) 2024-10-17
MX2024012034A (es) 2025-03-07
CA3246987A1 (en) 2023-10-05
EP4499826A1 (en) 2025-02-05
CN119790153A (zh) 2025-04-08

Similar Documents

Publication Publication Date Title
CA3136735A1 (en) Methods and compositions for editing rnas
US9523093B2 (en) Huntington's disease therapeutic compounds
EP2673286B1 (en) Therapeutic compounds
US20090215862A1 (en) Micro rna
JP2015524264A (ja) 遺伝子発現の下方制御のための核酸
US20100086526A1 (en) Nucleic acid constructs and methods for specific silencing of h19
EP3635120A1 (en) Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
US20260002152A1 (en) Antisense Nucleic Acids for Use in the Treatment for LMNA Mutation Carriers
WO2017087828A1 (en) Method to modulate smooth muscle cell differentiation
TW201119681A (en) Compositions and methods for inhibiting expression of KIF10 genes
KR101420564B1 (ko) ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
US10920195B2 (en) Methods to generate epithelial cells
Haraguchi et al. SiRNAs do not induce RNA-dependent transcriptional silencing of retrovirus in human cells
JP4505566B2 (ja) 肺癌治療剤
US20250215436A1 (en) Antisense Nucleic Acids for Use in the Treatment for KCNQ1 Mutation Carriers
JP2025135809A (ja) マイクロｒｎａ発現カセット、発現ベクター、及びそれらの利用
WO2024251244A9 (zh) 多核苷酸、药物组合物及其用途
KR20240128053A (ko) USH2A pre-mRNA를 표적으로 하는 SnRNA 및 이의 용도
JP5273740B2 (ja) ｐ５３の発現促進方法およびそれに用いるｐ５３発現促進剤
KR20210074227A (ko) Myc 인핸서 결실용 가이드 rna 및 이의 용도
WO2019036871A1 (zh) 特异敲低人miR-148a、miR-185和miR-424表达的Tud RNA及其应用
WO2019033246A1 (zh) 共敲减三种 miRNA 表达的 Tud RNA 及其应用
HK1236224A1 (en) Huntington's disease therapeutic compounds
HK1236224B (en) Huntington's disease therapeutic compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241029

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application